Ember Therapeutics

Therapeutics based on bone morphogenic protein - 7

placeNew York City, New York, United States calendar_todayFounded 2011 groups1 employees language embertx.com

Registered entities

Innovation

4 patent families (1 granted) — focus: Chemistry & metallurgy; filing pace dormant. Cited 107 times.

YearFilings
20132
20151
20161

Investor mix

2 investors on record; lead investors include Third Rock Ventures.

Investor typeCountShare
Venture capital150%
Other / undisclosed150%
Coming soon